Development of novel amyloid imaging agents based upon thioflavin S

Jingjun Wei, Chunying Wu, David Lankin, Anil Gulrati, Tibor Valyi-Nagy, Elizabeth Cochran, Victor W. Pike, Alan Kozikowski, Yanming Wang

Research output: Contribution to journalArticle

Abstract

To date, small-molecule amyloid-imaging agents for in vivo detection and quantitation of amyloid deposits in Alzheimer's disease (AD) have been developed and successfully applied to human subjects. Preliminary studies have indicated that these amyloid-imaging agents were accumulated in the AD brains in a pattern that is relatively consistent with AD pathology, at least in the regions of amyloid-rich grey matter. These studies have also proven the concept that amyloid dyes, normally too hydrophilic to enter the brain, can be chemically modified to enhance brain permeability, binding affinity, as well as improve binding specificity for amyloid deposits. Related studies have suggested that structurally different agents can be developed that bind to different sites on amyloid deposits. In fact, in vivo cross-referencing studies based upon different amyloid-imaging agents may permit better characterization of AD pathology. But more importantly, novel amyloid imaging agents are required that will allow direct correlation between the results of animal models and human subjects based upon identical imaging modalities. Thus far, amyloid stains such as Congo red and thioflavin T have been extensively studied. However, another widely used amyloid dye, thioflavin S, has not been previously explored. This is in part due to the fact that thioflavin S exists as a mixture, not a pure chemical entity, albeit that the major component has been characterized. We hypothesized that neutral analogs, based upon the major component, could be developed as novel amyloid imaging agents, that exhibit complementary binding properties and pharmacokinetic profiles compatible with potential human studies.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalCurrent Alzheimer Research
Volume2
Issue number2
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Amyloid
Amyloid Plaques
Alzheimer Disease
Coloring Agents
Brain
Pathology
thioflavin T
Congo Red
Permeability
Animal Models
Pharmacokinetics

Keywords

  • Alzheimer's disease
  • Amyloid
  • Congo red
  • Thioflavin S
  • Thioflavin T

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Wei, J., Wu, C., Lankin, D., Gulrati, A., Valyi-Nagy, T., Cochran, E., ... Wang, Y. (2005). Development of novel amyloid imaging agents based upon thioflavin S. Current Alzheimer Research, 2(2), 109-114. https://doi.org/10.2174/1567205053585864

Development of novel amyloid imaging agents based upon thioflavin S. / Wei, Jingjun; Wu, Chunying; Lankin, David; Gulrati, Anil; Valyi-Nagy, Tibor; Cochran, Elizabeth; Pike, Victor W.; Kozikowski, Alan; Wang, Yanming.

In: Current Alzheimer Research, Vol. 2, No. 2, 04.2005, p. 109-114.

Research output: Contribution to journalArticle

Wei, J, Wu, C, Lankin, D, Gulrati, A, Valyi-Nagy, T, Cochran, E, Pike, VW, Kozikowski, A & Wang, Y 2005, 'Development of novel amyloid imaging agents based upon thioflavin S', Current Alzheimer Research, vol. 2, no. 2, pp. 109-114. https://doi.org/10.2174/1567205053585864
Wei J, Wu C, Lankin D, Gulrati A, Valyi-Nagy T, Cochran E et al. Development of novel amyloid imaging agents based upon thioflavin S. Current Alzheimer Research. 2005 Apr;2(2):109-114. https://doi.org/10.2174/1567205053585864
Wei, Jingjun ; Wu, Chunying ; Lankin, David ; Gulrati, Anil ; Valyi-Nagy, Tibor ; Cochran, Elizabeth ; Pike, Victor W. ; Kozikowski, Alan ; Wang, Yanming. / Development of novel amyloid imaging agents based upon thioflavin S. In: Current Alzheimer Research. 2005 ; Vol. 2, No. 2. pp. 109-114.
@article{e103918384394e98a26b7d6c64cb275d,
title = "Development of novel amyloid imaging agents based upon thioflavin S",
abstract = "To date, small-molecule amyloid-imaging agents for in vivo detection and quantitation of amyloid deposits in Alzheimer's disease (AD) have been developed and successfully applied to human subjects. Preliminary studies have indicated that these amyloid-imaging agents were accumulated in the AD brains in a pattern that is relatively consistent with AD pathology, at least in the regions of amyloid-rich grey matter. These studies have also proven the concept that amyloid dyes, normally too hydrophilic to enter the brain, can be chemically modified to enhance brain permeability, binding affinity, as well as improve binding specificity for amyloid deposits. Related studies have suggested that structurally different agents can be developed that bind to different sites on amyloid deposits. In fact, in vivo cross-referencing studies based upon different amyloid-imaging agents may permit better characterization of AD pathology. But more importantly, novel amyloid imaging agents are required that will allow direct correlation between the results of animal models and human subjects based upon identical imaging modalities. Thus far, amyloid stains such as Congo red and thioflavin T have been extensively studied. However, another widely used amyloid dye, thioflavin S, has not been previously explored. This is in part due to the fact that thioflavin S exists as a mixture, not a pure chemical entity, albeit that the major component has been characterized. We hypothesized that neutral analogs, based upon the major component, could be developed as novel amyloid imaging agents, that exhibit complementary binding properties and pharmacokinetic profiles compatible with potential human studies.",
keywords = "Alzheimer's disease, Amyloid, Congo red, Thioflavin S, Thioflavin T",
author = "Jingjun Wei and Chunying Wu and David Lankin and Anil Gulrati and Tibor Valyi-Nagy and Elizabeth Cochran and Pike, {Victor W.} and Alan Kozikowski and Yanming Wang",
year = "2005",
month = "4",
doi = "10.2174/1567205053585864",
language = "English (US)",
volume = "2",
pages = "109--114",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Development of novel amyloid imaging agents based upon thioflavin S

AU - Wei, Jingjun

AU - Wu, Chunying

AU - Lankin, David

AU - Gulrati, Anil

AU - Valyi-Nagy, Tibor

AU - Cochran, Elizabeth

AU - Pike, Victor W.

AU - Kozikowski, Alan

AU - Wang, Yanming

PY - 2005/4

Y1 - 2005/4

N2 - To date, small-molecule amyloid-imaging agents for in vivo detection and quantitation of amyloid deposits in Alzheimer's disease (AD) have been developed and successfully applied to human subjects. Preliminary studies have indicated that these amyloid-imaging agents were accumulated in the AD brains in a pattern that is relatively consistent with AD pathology, at least in the regions of amyloid-rich grey matter. These studies have also proven the concept that amyloid dyes, normally too hydrophilic to enter the brain, can be chemically modified to enhance brain permeability, binding affinity, as well as improve binding specificity for amyloid deposits. Related studies have suggested that structurally different agents can be developed that bind to different sites on amyloid deposits. In fact, in vivo cross-referencing studies based upon different amyloid-imaging agents may permit better characterization of AD pathology. But more importantly, novel amyloid imaging agents are required that will allow direct correlation between the results of animal models and human subjects based upon identical imaging modalities. Thus far, amyloid stains such as Congo red and thioflavin T have been extensively studied. However, another widely used amyloid dye, thioflavin S, has not been previously explored. This is in part due to the fact that thioflavin S exists as a mixture, not a pure chemical entity, albeit that the major component has been characterized. We hypothesized that neutral analogs, based upon the major component, could be developed as novel amyloid imaging agents, that exhibit complementary binding properties and pharmacokinetic profiles compatible with potential human studies.

AB - To date, small-molecule amyloid-imaging agents for in vivo detection and quantitation of amyloid deposits in Alzheimer's disease (AD) have been developed and successfully applied to human subjects. Preliminary studies have indicated that these amyloid-imaging agents were accumulated in the AD brains in a pattern that is relatively consistent with AD pathology, at least in the regions of amyloid-rich grey matter. These studies have also proven the concept that amyloid dyes, normally too hydrophilic to enter the brain, can be chemically modified to enhance brain permeability, binding affinity, as well as improve binding specificity for amyloid deposits. Related studies have suggested that structurally different agents can be developed that bind to different sites on amyloid deposits. In fact, in vivo cross-referencing studies based upon different amyloid-imaging agents may permit better characterization of AD pathology. But more importantly, novel amyloid imaging agents are required that will allow direct correlation between the results of animal models and human subjects based upon identical imaging modalities. Thus far, amyloid stains such as Congo red and thioflavin T have been extensively studied. However, another widely used amyloid dye, thioflavin S, has not been previously explored. This is in part due to the fact that thioflavin S exists as a mixture, not a pure chemical entity, albeit that the major component has been characterized. We hypothesized that neutral analogs, based upon the major component, could be developed as novel amyloid imaging agents, that exhibit complementary binding properties and pharmacokinetic profiles compatible with potential human studies.

KW - Alzheimer's disease

KW - Amyloid

KW - Congo red

KW - Thioflavin S

KW - Thioflavin T

UR - http://www.scopus.com/inward/record.url?scp=20844451743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844451743&partnerID=8YFLogxK

U2 - 10.2174/1567205053585864

DO - 10.2174/1567205053585864

M3 - Article

C2 - 15974905

AN - SCOPUS:20844451743

VL - 2

SP - 109

EP - 114

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 2

ER -